Recent development of new agents with specific molecular targets, especially epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), has enhanced scientific interest in particular gene mutations and challenged some of the established paradigms in the therapeutic intervention of NSCLC [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.